Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN SODIUM versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN SODIUM versus ONMEL.
IBUPROFEN SODIUM vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
50 mg orally twice daily for 14 days
None Documented
None Documented
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category D/X
Category C
NSAID
NSAID